Publicaciones en las que colabora con Francisco José Muruzábal (35)

2023

  1. Beneficial Effects of Plasma Rich in Growth Factors (PRGF) Versus Autologous Serum and Topical Insulin in Ocular Surface Cells

    Current Eye Research, Vol. 48, Núm. 5, pp. 456-464

  2. Biological and Adhesive Properties of an Autologous Protein-Based Fibrin Sealant for Ophthalmological Applications

    Translational Vision Science and Technology, Vol. 12, Núm. 11

  3. Development of a new plasma rich in growth factors membrane with improved optical properties

    Annals of Anatomy, Vol. 248

  4. PRGF Membrane with Tailored Optical Properties Preserves the Cytoprotective Effect of Plasma Rich in Growth Factors: In Vitro Model of Retinal Pigment Epithelial Cells

    International Journal of Molecular Sciences, Vol. 24, Núm. 13

2022

  1. Differential Protein Content between Fresh and Freeze-Dried Plasma Rich in Growth Factors Eye Drops

    Biomolecules, Vol. 12, Núm. 9

  2. Optimization of a Plasma Rich in Growth Factors Membrane for the Treatment of Inflammatory Ocular Diseases

    Bioengineering, Vol. 9, Núm. 10

  3. Progress in the use of plasma rich in growth factors in ophthalmology: from ocular surface to ocular fundus

    Expert Opinion on Biological Therapy, Vol. 22, Núm. 1, pp. 31-45

2021

  1. Development and optimization of a personalized fibrin membrane derived from the plasma rich in growth factors technology

    Experimental Eye Research, Vol. 203

  2. Plasma rich in growth factors versus Mitomycin C in photorefractive keratectomy

    Medicine, Vol. 100, Núm. 3, pp. e24139

  3. Proteomic characterization of plasma rich in growth factors and undiluted autologous serum

    International Journal of Molecular Sciences, Vol. 22, Núm. 22

  4. Stability of freeze-dried plasma rich in growth factors eye drops stored for 3 months at different temperature conditions

    European Journal of Ophthalmology, Vol. 31, Núm. 2, pp. 354-360

  5. Use of plasma rich in growth factors and regenerating agent matrix for the treatment of corneal diseases

    Vision (Switzerland), Vol. 5, Núm. 3

2020

  1. Antioxidant role of PRGF on RPE cells after blue light insult as a therapy for neurodegenerative diseases

    International Journal of Molecular Sciences, Vol. 21, Núm. 3

  2. Development and optimization of freeze-dried eye drops derived from plasma rich in growth factors technology

    Translational Vision Science and Technology, Vol. 9, Núm. 7, pp. 1-16

  3. Plasma rich in growth factors enhances cell survival after in situ retinal degeneration

    International Journal of Molecular Sciences, Vol. 21, Núm. 20, pp. 1-16

  4. Plasma rich in growth factors for the treatment of dry eye from patients with graft versus host diseases

    European Journal of Ophthalmology, Vol. 30, Núm. 1, pp. 94-103

  5. Plasma rich in growth factors reduces blue light-induced oxidative damage on retinal pigment epithelial cells and restores their homeostasis by modulating vascular endothelial growth factor and pigment epithelium-derived factor expression

    Clinical and Experimental Ophthalmology, Vol. 48, Núm. 6, pp. 830-838

2019

  1. Galenic validation of plasma rich in growth factors eye drops

    Farmacia Hospitalaria, Vol. 43, Núm. 2, pp. 45-49

2018

  1. Differential profile of protein expression on human keratocytes treated with autologous serum and plasma rich in growth factors (PRGF)

    PLoS ONE, Vol. 13, Núm. 10

  2. PRGF in equine corneal cells: A standardised protocol is the key to achieve accurate results

    Equine Veterinary Journal